WO2025006965 - METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN
National phase entry is expected:
Publication Number
WO/2025/006965
Publication Date
02.01.2025
International Application No.
PCT/US2024/036129
International Filing Date
28.06.2024
Title **
[English]
METHODS OF ADMINISTERING SOLRIAMFETOL TO LACTATING WOMEN
[French]
PROCÉDÉS D'ADMINISTRATION DE SOLRIAMFÉTOL À DES FEMMES EN LACTATION
Applicants **
AXSOME THERAPEUTICS, INC.
One World Trade Center
22nd Floor
New York, NY 10007, US
Inventors
TABUTEAU, Herriot
206 Park Avenue South, Apt 7B
New York, NY 10010, US
Priority Data
63/510,981
29.06.2023
US
63/592,313
23.10.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2194 | |
| EPO | Filing, Examination | 18110 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 608 | |
| USA | Filing, Examination | 12110 |
Total: 33619 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.[French]
Selon certains modes de réalisation, l'invention concerne un procédé destiné à diminuer le potentiel d'événements indésirables causés par du solriamfétol dans un lait maternel, ingéré par un nourrisson, obtenu d'un sujet traité avec du solriamfétol comprenant : l'administration orale du solriamfétol au sujet à une dose quotidienne d'environ 37,5 mg à environ 300 mg ; et l'ingestion du lait maternel infantile du sujet au moins environ 5 heures après l'administration du solriamfétol au sujet, ce qui permet de diminuer le potentiel d'événements indésirables causés par du solriamfétol chez un nourrisson.